These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17885672)

  • 1. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas).
    Lerma E; Peiro G; Ramón T; Fernandez S; Martinez D; Pons C; Muñoz F; Sabate JM; Alonso C; Ojeda B; Prat J; Barnadas A
    Mod Pathol; 2007 Nov; 20(11):1200-7. PubMed ID: 17885672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas).
    Rakha EA; Ellis IO; Reis-Filho JS
    Mod Pathol; 2008 Aug; 21(8):1060-1; author reply 1061-2. PubMed ID: 18654595
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basal-like immunophenotype markers and prognosis in early breast cancer.
    Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
    Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
    Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
    Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
    Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.
    Bryan BB; Schnitt SJ; Collins LC
    Mod Pathol; 2006 May; 19(5):617-21. PubMed ID: 16528377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison Between HER2, Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases.
    Desouki MM; Atta IS; Wolff DJ; Self SE
    Turk Patoloji Derg; 2016; 32(3):178-85. PubMed ID: 27562392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas.
    Cimino-Mathews A; Subhawong AP; Elwood H; Warzecha HN; Sharma R; Park BH; Taube JM; Illei PB; Argani P
    Hum Pathol; 2013 Jun; 44(6):959-65. PubMed ID: 23260325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.
    Niemeier LA; Dabbs DJ; Beriwal S; Striebel JM; Bhargava R
    Mod Pathol; 2010 Feb; 23(2):205-12. PubMed ID: 19898421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
    Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
    Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
    Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD
    Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR expression and activation are common in HER2 positive and triple-negative breast tumours.
    Koletsa T; Kotoula V; Karayannopoulou G; Nenopoulou E; Karkavelas G; Papadimitriou CS; Kostopoulos I
    Histol Histopathol; 2010 Sep; 25(9):1171-9. PubMed ID: 20607659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast carcinoma in Uganda: microscopic study and receptor profile of 45 cases.
    Roy I; Othieno E
    Arch Pathol Lab Med; 2011 Feb; 135(2):194-9. PubMed ID: 21284437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
    Fadare O; Wang SA; Hileeto D
    Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu.
    Bouras T; Southey MC; Venter DJ
    Cancer Res; 2001 Feb; 61(3):903-7. PubMed ID: 11221879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes.
    Niwińska A; Olszewski W; Murawska M; Pogoda K
    J Neurooncol; 2011 Dec; 105(3):547-53. PubMed ID: 21656328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.
    Shokouh TZ; Ezatollah A; Barand P
    Medicine (Baltimore); 2015 Aug; 94(32):e1359. PubMed ID: 26266392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.
    Dabbs DJ; Chivukula M; Carter G; Bhargava R
    Mod Pathol; 2006 Nov; 19(11):1506-11. PubMed ID: 16941011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.